Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on the drugmaker’s guidance amid U.S. President Donald Trump’s ongoing threats to impose tariffs on the sector.

Net income: $15.3 million, or $0.86 per diluted share (GAAP) in Q2 2025; adjusted to $16.6 million, or $0.94 per diluted share, excluding M&A and debt extinguishment costs, in Q2 2025.

Looming U.S. tariffs, together with a real estate market slump feeding into weakening consumer confidence, saw China's GDP growth slow in the second quarter.

Guangzhou Automobile Group (GAC) and JAC Group expect to post their biggest ever second-quarter losses next month, as the state-owned Chinese automakers struggle with competition at home and abroad.

Investors will closely monitor the company's performance against ongoing challenges, such as macroeconomic pressures and tariff

State Street reports strong Q2 results with cost controls and asset inflows but faces pricing pressures. Click here to read my most recent analysis of STT.

EV sales dipped 6.3% as buyers awaited tax credit changes, with GM gaining share and used EV sales reaching a new record.

For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful insights.

S&P 500 EPS growth is expected to come in at 4.8% for Q2, which would be the lowest growth rate since Q4 2023.